In February 2021, Cryo-Cell entered into an exclusive license agreement with Duke University, gaining rights to use proprietary processes and regulatory data related to cord blood and cord tissue. Cryo-Cell had intended to open an infusion clinic and be a site for clinical trials and expanded access protocols for conditions like cerebral palsy, autism, and other neurological disorders.
While our collaboration with Duke University was founded on a clear commitment to help families by significantly expanding and accelerating access to emerging cellular therapies, that agreement ended as of May 17, 2025. As a direct result, Cryo-Cell will not be moving forward with the infusion clinic previously planned under this agreement. For the most current information, all inquiries related to programs or therapies developed during this past collaboration are being redirected to Duke University.
Our core mission at Cryo-Cell remains unchanged: to provide families with premier cord blood and cord tissue banking services to safeguard their family's future health. As a pioneer in the industry, our dedication to scientific integrity, quality, and our client families is unwavering. We are actively pursuing and investing in innovative opportunities to help unlock the full potential of newborn stem cells. We thank you for your continued trust in Cryo-Cell.